Trial on Vascular Inflammation in Atopic Dermatitis
Vascular Inflammation and Coronary Atherosclerosis Risks in Subjects With Atopic Dermatitis
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
Quebec
-
Montreal, Quebec, Canada, H3K 4L5
- Innovaderm Research Inc
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Main inclusion Criteria:
- Men or women
- 18 years of age or older at time of consent.
- For AD subjects only: Confirmed clinical diagnosis of active AD according to Hanifin and Rajka criteria, BSA, EASI and IGA.
- For AD subjects only: Diagnosis of atopic dermatitis for at least 5 years.
- Women of childbearing potential is willing to use effective contraceptive method.
- Women of childbearing potential must have a negative urine pregnancy test.
Main exclusion Criteria:
- Has known cardiovascular arterial disease, a pacemaker, psoriasis, uncontrolled diabetes.
- Presence of an unstable co-morbidity that could have an effect on vascular inflammation.
- Heart rate restriction for patients with asthma or COPD.
- Use of any topical medication for atopic dermatitis on the site to be biopsied.
- Use of systemic treatments for atopic dermatitis.
- Use of phototherapy, tanning booth or other ultraviolet light sources.
- Use of biologics.
- Use of experimental medications.
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Atopic Dermatis Subjects
30 subjects with atopic dermatitis
|
a 18FDG-PET to quantify vascular inflammation
a MDCT to calculate the Agatston score
biopsy and blood collection to assess biomarkers
|
|
Healthy Volunteers
30 subjects without AD that matches for sex, age (± 2 years) and coronary artery disease risk factor with the AD subjects will be included as control case
|
a 18FDG-PET to quantify vascular inflammation
a MDCT to calculate the Agatston score
biopsy and blood collection to assess biomarkers
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Target to background ratio (TBR) from the ascending aorta
Time Frame: 0 Days
|
0 Days
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Target to background ratio (TBR) from the carotids
Time Frame: 0 Days
|
0 Days
|
|
Agatston score
Time Frame: 0 Days
|
0 Days
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Correlation between target to background ratio (TBR) and biomarkers, AD severity measurements (EASI, BSA, IGA and SCORAD), endothelial cell-derived micro particles.
Time Frame: 0 Days
|
0 Days
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Innovaderm Research clinical site, Innovaderm Research clinical site
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (ACTUAL)
Primary Completion
Study Completion (ACTUAL)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
First Posted
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Heart Diseases
- Cardiovascular Diseases
- Vascular Diseases
- Skin Diseases
- Immune System Diseases
- Arteriosclerosis
- Arterial Occlusive Diseases
- Hypersensitivity, Immediate
- Genetic Diseases, Inborn
- Skin Diseases, Genetic
- Hypersensitivity
- Coronary Disease
- Skin Diseases, Eczematous
- Coronary Artery Disease
- Myocardial Ischemia
- Inflammation
- Dermatitis
- Eczema
- Atherosclerosis
- Dermatitis, Atopic
Other Study ID Numbers
Other Study ID Numbers
- Inno-6043
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.